Key facts
- Augustine Therapeutics’s last known valuation is $73.5M (Mar 2025).
- It has raised $93.4M; the latest was Later Stage VC ($83.3M) in Mar 2025.
- Notable investors include Novo Holdings, Participatiemaatschappij Vlaanderen, Asabys Partners, Eli Lilly and Company Foundation, VIB — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Augustine Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Augustine Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Augustine Therapeutics
Developer of therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases. The company's drugs have the potential to protect from nerve degeneration and promote peripheral myelin repair, enabling healthcare providers to improve the lives of patients and cure them.
- Sector
- Healthcare
- HQ
- Leuven, Belgium
- Founded
- 2019
- Employees
- 23
- Website
- augustinetx.com/
- Ownership
- Privately Held (backing)
Augustine Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Augustine Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Augustine Therapeutics in its N-PORT filings yet. We sweep new filings monthly.